Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis
Open Access
- 29 April 2009
- journal article
- vasculitis
- Published by Wiley in Arthritis & Rheumatism
- Vol. 60 (5), 1540-1547
- https://doi.org/10.1002/art.24454
Abstract
Objective To investigate the efficacy of rituximab in patients with refractory ophthalmic Wegener's granulomatosis (WG). Methods Data from 10 consecutive patients with refractory ophthalmic WG treated with rituximab were retrospectively reviewed. In all patients, the ophthalmic disease was driving treatment decisions, and disease activity had persisted despite standard immunosuppressive treatment. Patients had refractory scleritis (n = 3), orbital granulomas causing optic nerve compromise (n = 4), or a combination of both conditions (n = 3). All patients had been treated with at least 3 different immunosuppressive agents, and 5 patients had previously been treated with tumor necrosis factor α blockade. Rituximab was administered intravenously in 2 doses, 2 weeks apart, in combination with standard treatment. Disease activity was monitored clinically by an interdisciplinary approach, including disease activity scoring, immunodiagnostics, and magnetic resonance imaging, as well as by corresponding reductions in the required dose of conventional medication. Results A beneficial response to treatment with rituximab was seen in all 10 patients, including induction of clinical remission. In all patients, the peripheral blood B cell count fell to zero during treatment with rituximab. Titers of classic antineutrophil cytoplasmic antibodies fell in association with B cell counts, and this reduction was correlated with improved clinical findings. Conclusion In contrast to previous observations, this study showed that treatment with rituximab was associated with clinical improvement in patients with refractory ophthalmic WG.Keywords
This publication has 41 references indexed in Scilit:
- Idiopathic retroperitoneal fibrosis: a role for mycophenolate mofetilClinical Nephrology, 2008
- Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of responseAnnals Of The Rheumatic Diseases, 2007
- Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosisBritish Journal of Ophthalmology, 2007
- EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitisAnnals Of The Rheumatic Diseases, 2007
- Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Successful treatment of Wegener's granulomatosis associated scleritis with rituximabBritish Journal of Ophthalmology, 2005
- Orbital socket contracture: a complication of inflammatory orbital disease in patients with Wegener's granulomatosisBritish Journal of Ophthalmology, 2005
- Rituximab Induced Remission in a Patient with Wegener’s GranulomatosisNephron Clinical Practice, 2005
- Cells perpetuating the inflammatory response in scleritis.British Journal of Ophthalmology, 1994
- Nomenclature of Systemic VasculitidesArthritis & Rheumatism, 1994